Research programme: cancer immunotherapies - BioMed X/Ono Pharmaceutical
Latest Information Update: 05 Jan 2024
At a glance
- Originator BioMed X; Ono Pharmaceutical
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer